Which has a little better prospects, QC or analytical researcher in a pharmaceutical company?

Researchers have better prospects.

After all, there are two words of research, stained with these two words, are to translate the literature, access to information, most of the United States, the European Union, Japan and so on.

qc, is to follow the production, every day to complete the normal inspection of the product, out of the report on the line, generally go to the Chinese Pharmacopoeia, the provincial and departmental inspection methods, the difficulty is not great.

If you look at the money Income, not necessarily, the probability that the researcher's salary is a little higher, a small number of pharmaceutical companies pay special attention to the quality of the link, there are qc than the researcher's salary is high.

While the work done, the operation of the instrument are not very different, but the preliminary need is not quite the same.

In my opinion, quality researcher is better, can make drugs, and R&D sounds a bit more high-end.

China's pharmaceutical industry after a longer round of sustained high-speed growth, affecting the development of the industry's various contradictions gradually revealed, China's pharmaceutical industry has entered a crisis and turnaround coexisting critical development period.

How is the future development of China's pharmaceutical industry, the market competition pattern how to evolve, how to cope with a new round of pharmaceutical enterprises in the market competition and reshuffle reorganization, which pharmaceutical companies can get the right to survive in the future? We must stand in the height of industrial development for rational thinking, serious preparation, active response.

Western industrial history brings us inspiration:

The Morgan era of the North American industry (1880~1920) is an important period in the history of Western industrial development, during which the state of market competition and industrial restructuring, the development of today's pharmaceutical industry has an important reference significance for us.

The competitive pattern of the industry at that time was low-level duplication of construction, manufacturers, vicious competition, price wars, smoke and confusion in the market order, the survival of manufacturers in the industry is difficult, a struggle.

Financial capitalist JP Morgan rose to save themselves, drive, dominate the United States industrial reorganization. JP Morgan acquired Carnegie Steel, annexed 785 small steel companies, the formation of the famous U.S. Steel, the assets of 1.5 billion U.S. dollars, is the world's first assets of more than 1 billion U.S. dollars in the company, control of U.S. steel production of 70%.

Subsequently, Rockefeller pushed more than 40 oil companies to form a trust, the formation of Mobil Oil; Durant pushed more than 200 automobile companies to merge into General Motors, with Ford **** in charge of the auto industry order.

This wave of industrial reorganization reached almost all industrial sectors, metal raw materials, petroleum, metal processing and other industries particularly strong. The pattern of industrial over-competition has been completely changed, economies of scale can be realized, the rise of the United States of America's modern big industry, completely opened with the European industrial competitiveness gap.

The U.S. pharmaceutical industry also experienced this industrial reorganization process. At the end of the 19th century and the beginning of the 20th century, the number of pharmaceutical companies in the United States had reached more than 3,000. In the following 20 ~ 30 years, nearly half of the pharmaceutical companies out of the market, after a century of market competition and mergers and acquisitions, the U.S. pharmaceutical industry structure continues to adjust, optimize and upgrade, market concentration increased significantly.

Today, there are only a few hundred pharmaceutical companies in the U.S. They are either highly competitive multinational pharmaceutical conglomerates or high-tech biopharmaceutical companies that specialize in the development of specialties.

Looking at the development and change of western industrial history, China's pharmaceutical industry has too many similarities with the Morgan era of North American industrial history. Learning from history, the development of China's pharmaceutical industry is predicted to show the following development trend: the normalization of low-cost competition.